Campbell & CO Investment Adviser LLC Makes New Investment in Dr.Reddy’s Laboratories Ltd (NYSE:RDY)

Campbell & CO Investment Adviser LLC acquired a new position in shares of Dr.Reddy’s Laboratories Ltd (NYSE:RDY) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 3,945 shares of the company’s stock, valued at approximately $209,000.

Other institutional investors have also modified their holdings of the company. Thrivent Financial for Lutherans grew its position in Dr.Reddy’s Laboratories by 20.9% during the 1st quarter. Thrivent Financial for Lutherans now owns 34,498 shares of the company’s stock worth $1,392,000 after purchasing an additional 5,953 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in Dr.Reddy’s Laboratories by 5.7% during the 1st quarter. Parametric Portfolio Associates LLC now owns 664,317 shares of the company’s stock worth $26,792,000 after purchasing an additional 35,857 shares during the last quarter. Bank of America Corp DE grew its position in Dr.Reddy’s Laboratories by 25.8% during the 4th quarter. Bank of America Corp DE now owns 242,982 shares of the company’s stock worth $9,861,000 after purchasing an additional 49,882 shares during the last quarter. State Street Corp grew its position in Dr.Reddy’s Laboratories by 39.6% during the 1st quarter. State Street Corp now owns 1,027,386 shares of the company’s stock worth $41,434,000 after purchasing an additional 291,320 shares during the last quarter. Finally, Schroder Investment Management Group grew its position in Dr.Reddy’s Laboratories by 120.4% during the 1st quarter. Schroder Investment Management Group now owns 529,099 shares of the company’s stock worth $22,402,000 after purchasing an additional 289,002 shares during the last quarter. 12.88% of the stock is currently owned by institutional investors.

Several brokerages have recently weighed in on RDY. ValuEngine downgraded shares of Dr.Reddy’s Laboratories from a “hold” rating to a “sell” rating in a report on Tuesday, July 7th. Nomura Instinet reaffirmed a “buy” rating on shares of Dr.Reddy’s Laboratories in a report on Tuesday, April 21st. Finally, Barclays lifted their target price on shares of Dr.Reddy’s Laboratories from $45.00 to $53.00 and gave the company an “equal weight” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. Dr.Reddy’s Laboratories has a consensus rating of “Hold” and a consensus price target of $53.00.

Shares of NYSE:RDY opened at $60.80 on Friday. The company has a market cap of $9.93 billion, a price-to-earnings ratio of 24.97 and a beta of 0.49. The firm’s 50-day simple moving average is $53.41 and its 200-day simple moving average is $47.63. The company has a quick ratio of 1.31, a current ratio of 1.66 and a debt-to-equity ratio of 0.04. Dr.Reddy’s Laboratories Ltd has a fifty-two week low of $33.33 and a fifty-two week high of $60.95.

Dr.Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Wednesday, May 20th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.12. The firm had revenue of $588.00 million for the quarter, compared to the consensus estimate of $552.28 million. Dr.Reddy’s Laboratories had a net margin of 10.26% and a return on equity of 18.88%. On average, research analysts forecast that Dr.Reddy’s Laboratories Ltd will post 1.84 EPS for the current year.

The business also recently disclosed an annual dividend, which was paid on Friday, July 10th. Investors of record on Friday, January 1st were issued a dividend of $0.3304 per share. The ex-dividend date was Friday, July 10th. This represents a yield of 0.5%. This is an increase from Dr.Reddy’s Laboratories’s previous annual dividend of $0.27. Dr.Reddy’s Laboratories’s payout ratio is currently 9.68%.

Dr.Reddy’s Laboratories Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

See Also: How to Invest in Growth Stocks

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr.Reddy’s Laboratories Ltd (NYSE:RDY).

Institutional Ownership by Quarter for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.